



September 20, 2012

SBI Pharmaceuticals Co., Ltd.

**Notice on the Appointment of a New Executive Officer**

SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new executive officer was appointed effective September 20, 2012.

**1. The name of the new executive officer**

Kyoko Imamura

**2. The career of the new executive officer**

Having graduated from the School of Medicine at Kumamoto University in 1982, Imamura served as an assistant in the Orthopedics Department of The Jikei University School of Medicine, and studied at Harvard University from 1986. In 1990, she obtained a PhD in medicine (clinical pharmacology) from The Jikei University School of Medicine. She studied at The University of London from 1992, and was awarded a PhD (Outcomes Research) there. She was appointed Vice President of Medical Affairs at Janssen Pharmaceutical K.K. in 2005, and has been serving as Scientific Relations Officer at Janssen Pharmaceutical K.K. since 2010. Meanwhile, she serves as Chairperson of The Japanese Association of Pharmaceutical Medicine, a general incorporated foundation, and Director of ACRP-Japan, a general incorporated foundation. At these foundations, she has many years of experience in training medical specialists with the aim of promoting clinical trials in Japan, and in providing education and training to persons in charge of international joint clinical trials.

SBI Pharmaceuticals expects that Imamura will contribute to the Company’s future business expansion with her extensive knowledge, experience and personal networks in the field of clinical tests.

\*\*\*\*\*

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095